Altrubio Inc.
Records under this name other than the patents Altrubio Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 5 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 9,950,077 | Anti-folate receptor alpha (FRA) antibody-drug conjugates and methods of using thereof Lapsed on the fee record Ended Apr 24, 2026 · From the USPTO record | Lapsed on the fee record | Ended Apr 24, 2026 | From the USPTO record |
| US 9,943,610 | Hydrophilic self-immolative linkers and conjugates thereof Lapsed on the fee record Ended Apr 17, 2026 · From the USPTO record | Lapsed on the fee record | Ended Apr 17, 2026 | From the USPTO record |
| US 8,287,871 | Methods of Inducing Cell Death of an Activated T Cell with ANTI-PSGL-1 Antibodies Term ended Term ended May 10, 2025 · High confidence | Term ended | Term ended May 10, 2025 | High confidence |
| US 8,663,641 | Anti-PSGL-1 antibodies Term ended Ended no later than May 10, 2025 · From the USPTO record | Term ended | Ended no later than May 10, 2025 | From the USPTO record |
| US 10,030,075 | Methods of Treating with ANTI-PSGL-1 Antibodies Term ended Term ended May 10, 2025 · High confidence | Term ended | Term ended May 10, 2025 | High confidence |
| US 9,631,019 | Methods of Treating GVHD and Transplant Rejection with ANTI-PSGL-1 Antibodies Lapsed on the fee record Ended Apr 25, 2025 · High confidence | Lapsed on the fee record | Ended Apr 25, 2025 | High confidence |
| US 8,361,472 | Anti-PSGL-1 antibodies Lapsed on the fee record Ended Jan 29, 2025 · From the USPTO record | Lapsed on the fee record | Ended Jan 29, 2025 | From the USPTO record |
| US 9,408,923 | Hydrophilic self-immolative linkers and conjugates thereof Lapsed on the fee record Ended Aug 9, 2024 · From the USPTO record | Lapsed on the fee record | Ended Aug 9, 2024 | From the USPTO record |
| US 9,193,794 | Antibodies recognizing a carbohydrate containing epitope on CD-43 and CEA expressed on cancer cells and methods using same Lapsed on the fee record Ended Nov 24, 2023 · From the USPTO record | Lapsed on the fee record | Ended Nov 24, 2023 | From the USPTO record |
| US 9,089,614 | Hydrophilic self-immolative linkers and conjugates thereof Lapsed on the fee record Ended Jul 28, 2023 · From the USPTO record | Lapsed on the fee record | Ended Jul 28, 2023 | From the USPTO record |